PURPOSE: This phase II study evaluated bortezomib-based secondary induction and stem cell mobilization in 38 transplant-eligible patients with myeloma who had an incomplete and stalled response to, or had relapsed after, previous immunomodulatory drug-based induction. EXPERIMENTAL DESIGN: Patients received up to six 21-day cycles of bortezomib plus dexamethasone, with added liposomal doxorubicin for patients not achieving partial response or better by cycle 2 or very good partial response or better (≥VGPR) by cycle 4 (DoVeD), followed by bortezomib, high-dose cyclophosphamide, and filgrastim mobilization. Gene expression/signaling pathway analyses were conducted in purified CD34+ cells after bortezomib-based mobilization and compared against patients who received only filgrastim ± cyclophosphamide. Plasma samples were similarly analyzed for quantification of associated protein markers. RESULTS: The response rate to DoVeD relative to the pre-DoVeD baseline was 61%, including 39% ≥ VGPR. Deeper responses were achieved in 10 of 27 patients who received bortezomib-based mobilization; postmobilization response rate was 96%, including 48% ≥ VGPR, relative to the pre-DoVeD baseline. Median CD34+ cell yield was 23.2 × 10(6) cells/kg (median of 1 apheresis session). After a median follow-up of 46.6 months, median progression-free survival was 47.1 months from DoVeD initiation; 5-year overall survival rate was 76.4%. Grade ≥ 3 adverse events included thrombocytopenia (13%), hand-foot syndrome (11%), peripheral neuropathy (8%), and neutropenia (5%). Bortezomib-based mobilization was associated with modulated expression of genes involved in stem cell migration. CONCLUSION: Bortezomib-based secondary induction and mobilization could represent an alternative strategy for elimination of tumor burden in immunomodulatory drug-resistant patients that does not impact stem cell yield.
PURPOSE: This phase II study evaluated bortezomib-based secondary induction and stem cell mobilization in 38 transplant-eligible patients with myeloma who had an incomplete and stalled response to, or had relapsed after, previous immunomodulatory drug-based induction. EXPERIMENTAL DESIGN:Patients received up to six 21-day cycles of bortezomib plus dexamethasone, with added liposomal doxorubicin for patients not achieving partial response or better by cycle 2 or very good partial response or better (≥VGPR) by cycle 4 (DoVeD), followed by bortezomib, high-dose cyclophosphamide, and filgrastim mobilization. Gene expression/signaling pathway analyses were conducted in purified CD34+ cells after bortezomib-based mobilization and compared against patients who received only filgrastim ± cyclophosphamide. Plasma samples were similarly analyzed for quantification of associated protein markers. RESULTS: The response rate to DoVeD relative to the pre-DoVeD baseline was 61%, including 39% ≥ VGPR. Deeper responses were achieved in 10 of 27 patients who received bortezomib-based mobilization; postmobilization response rate was 96%, including 48% ≥ VGPR, relative to the pre-DoVeD baseline. Median CD34+ cell yield was 23.2 × 10(6) cells/kg (median of 1 apheresis session). After a median follow-up of 46.6 months, median progression-free survival was 47.1 months from DoVeD initiation; 5-year overall survival rate was 76.4%. Grade ≥ 3 adverse events included thrombocytopenia (13%), hand-foot syndrome (11%), peripheral neuropathy (8%), and neutropenia (5%). Bortezomib-based mobilization was associated with modulated expression of genes involved in stem cell migration. CONCLUSION:Bortezomib-based secondary induction and mobilization could represent an alternative strategy for elimination of tumor burden in immunomodulatory drug-resistant patients that does not impact stem cell yield.
Authors: James R Berenson; Ori Yellin; Chien-Shing Chen; Ravi Patel; Alberto Bessudo; Ralph V Boccia; Hank H Yang; Robert Vescio; Elizabeth Yung; Russell Mapes; Benjamin Eades; James D Hilger; Eric Wirtschafter; Jacqueline Hilger; Youram Nassir; Regina A Swift Journal: Br J Haematol Date: 2011-09-26 Impact factor: 6.998
Authors: Dominik Dytfeld; Kent A Griffith; Judah Friedman; Daniel Lebovic; Colleen Harvey; Mark S Kaminski; Andrzej J Jakubowiak Journal: Leuk Lymphoma Date: 2011-07
Authors: Shaji Kumar; Ian Flinn; Paul G Richardson; Parameswaran Hari; Natalie Callander; Stephen J Noga; A Keith Stewart; Francesco Turturro; Robert Rifkin; Jeffrey Wolf; Jose Estevam; George Mulligan; Hongliang Shi; Iain J Webb; S Vincent Rajkumar Journal: Blood Date: 2012-03-15 Impact factor: 22.113
Authors: Michele Cavo; S Vincent Rajkumar; Antonio Palumbo; Philippe Moreau; Robert Orlowski; Joan Bladé; Orhan Sezer; Heinz Ludwig; Meletios A Dimopoulos; Michel Attal; Pieter Sonneveld; Mario Boccadoro; Kenneth C Anderson; Paul G Richardson; William Bensinger; Hans E Johnsen; Nicolaus Kroeger; Gösta Gahrton; P Leif Bergsagel; David H Vesole; Hermann Einsele; Sundar Jagannath; Ruben Niesvizky; Brian G M Durie; Jesus San Miguel; Sagar Lonial Journal: Blood Date: 2011-03-29 Impact factor: 22.113
Authors: Heather Landau; Neeta Pandit-Taskar; Hani Hassoun; Adam Cohen; Alex Lesokhin; Nikoletta Lendvai; Pamela Drullinsky; Philip Schulman; Suresh Jhanwar; Elizabeth Hoover; Christina Bello; Elyn Riedel; Stephen D Nimer; Raymond L Comenzo Journal: Leuk Lymphoma Date: 2011-09-23
Authors: S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel Journal: Blood Date: 2011-02-03 Impact factor: 22.113
Authors: Andrzej J Jakubowiak; Kent A Griffith; Donna E Reece; Craig C Hofmeister; Sagar Lonial; Todd M Zimmerman; Erica L Campagnaro; Robert L Schlossman; Jacob P Laubach; Noopur S Raje; Tara Anderson; Melissa A Mietzel; Colleen K Harvey; Sandra M Wear; Jennifer C Barrickman; Craig L Tendler; Dixie-Lee Esseltine; Susan L Kelley; Mark S Kaminski; Kenneth C Anderson; Paul G Richardson Journal: Blood Date: 2011-05-19 Impact factor: 22.113
Authors: Artur Jurczyszyn; Jacek Czepiel; Joanna Gdula-Argasińska; William Perucki; Aleksander B Skotnicki; Marcin Majka Journal: J Cancer Date: 2015-01-05 Impact factor: 4.207
Authors: R Silvennoinen; P Anttila; M Säily; T Lundan; J Heiskanen; T M Siitonen; S Kakko; M Putkonen; H Ollikainen; V Terävä; A Kutila; K Launonen; A Räsänen; A Sikiö; M Suominen; P Bazia; K Kananen; T Selander; T Kuittinen; K Remes; E Jantunen Journal: Bone Marrow Transplant Date: 2015-10-05 Impact factor: 5.483
Authors: Maria K Angelopoulou; Pantelis Tsirkinidis; Georgios Boutsikas; Theodoros P Vassilakopoulos; Panayiotis Tsirigotis Journal: Biomed Res Int Date: 2014-08-14 Impact factor: 3.411
Authors: Weihuan Wang; Shuiliang Yu; Jay Myers; Yiwei Wang; William W Xin; Marwah Albakri; Alison W Xin; Ming Li; Alex Y Huang; Wei Xin; Christian W Siebel; Hillard M Lazarus; Lan Zhou Journal: Haematologica Date: 2017-07-20 Impact factor: 9.941